Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
AtriCure, a leader in treatments for atrial fibrillation (Afib), announced that it will release its third quarter 2020 financial results on November 5, 2020. A conference call to discuss these results will take place at 4:30 p.m. Eastern Time on the same day. AtriCure's innovative technologies, like the FDA-approved Isolator® Synergy™ Ablation System and the AtriClip® Left Atrial Appendage Exclusion System, are widely utilized by medical professionals for Afib management, affecting over 33 million people globally. For further details, visit AtriCure.com.